A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282

Cohen, Steven J.; Dobelbower, Ralph R.; Lipsitz, Stuart R.; Catalano, Paul J.; Sischy, Ben; Smith, Thomas J.; Haller, Daniel G.

doi:10.1016/j.ijrobp.2004.12.074

Cited by 131 publications

(66 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the report of Gastrointestinal Tumor Study Group (GITSG), 5-fluorouracil (5-Fu) based chemoradiation can increase survival of pancreatic cancer patients [4]. Several studies used 5-Fu based chemoradiation to treat LAPC and the improvement of resection rate varies [4][5][6]18]. Kim HJ et al found that in spite of the use of various chemoradiation protocols, it was impossible to downsize the tumor to obtain resectability and only one of 87 patients could be resected in that study [18].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy

Shan

2016

Pancreatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…The 5-fluorouracil (5-FU) based chemoradiotherapy has been supported as the most acceptable treatment [4][5][6]. In the recent decade, gemcitabine has been considered as the standard agent for advanced pancreatic cancer and also act as a radiosensitizer during radiotherapy [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy

Shan

2016

Pancreatology

View full text Add to dashboard Cite

“…Recent literature hasshownthatPC patientswithinvolvement of the adjacent mesenteric vessels who were undergoing R0 resections had the same survival outcomes as those who underwent resection for primarily resectable PC [10][11][12]. The main challenge in the surgical management of BRPC is the high rate of positive margins at the reconstructed vessel segments, leading to highriskoflocalandsystemic recurrence [13].Selectionofpatients who will benefit from neoadjuvant therapy or direct surgical resection is often challenging and highly dependent on the experience of multidisciplinary tumor board personnel.…”

Section: Stagingmentioning

confidence: 99%

“…More toxicities were reported in patients on the CRT arm [11]. A pooled analysis of the 794 patients in the GITSG 9273 and ECOG 8282 trials showed a significant OS advantage for CRT over RT alone [13].…”

Section: Chemoradiation Versus Radiation Alonementioning

confidence: 99%

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

Shaib

Cardona

et al. 2016

The Oncologist

View full text Add to dashboard Cite

Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) account for approximately 30% of newly diagnosed cases of PC. The objective of BRPC therapy is to downstage the tumor to allow resection; the objective of LAPC therapy is to control disease and improve survival. There is no consensus on the definitions of BRPC and LAPC, which leads to major limitations in designing clinical trials and evaluating their results. A multimodality approach is always needed to ensure proper utilization and timing of chemotherapy, radiation, and surgery in the management of this disease. Combination chemotherapy regimens (5-fluorouracil, leucovorin, irinotecan, oxaliplatin, and gemcitabine [FOLFIRINOX] and gemcitabine/nab-paclitaxel) have improved overall survival in metastatic disease. The role of combination chemotherapy regimens in BRPC and LAPC is an area of active investigation. There is no consensus on the dose, modality, and role of radiation therapy in the treatment of BRPC and LAPC. This article reviews the literature and highlights the areas of controversy regarding management of BRPC and LAPC. The Oncologist 2016;21:178-187 Implications for Practice: Pancreatic cancer is one of the worst cancers with regard to survival, even at early stages of the disease. This review evaluates all the evidence for the stages in which the cancer is not primarily resectable with surgery, known as borderline resectable or locally advanced unresectable. Recently, advancements in radiation techniques and use of better combination chemotherapies have improved survival and tolerance. There is no consensus on description of stages or treatment sequences (chemotherapy, chemoradiation, radiation), nor on the best chemotherapy regimen. The evidence behind the treatment paradigm for these stages of pancreatic cancer is summarized.

show abstract

“…Mimo znacznej liczby [119][120][121][122][123][124][125][126] dobrze zaplanowanych badań w małych grupach chorych przeprowadzanych w ciągu 30 lat rola radioterapii z zastosowaniem cytostatyków lub bez ich zastosowania nie została wystarczająco potwierdzona. Należy przypuszczać, że gdyby radioterapia miała istotne znaczenie w terapii raka trzustki, do tej pory znaleziono by na to dowody.…”

Section: Radioterapia Plus Lekiunclassified

Randomized trials in exocrine pancreatic cancer

Andrén‐Sandberg¹,

Hedberg²,

Winter³

et al. 2011

View full text Add to dashboard Cite

StreszczenieLeczenie raka trzustki jest poważnym problemem współczes -nej medycyny. Rak ten stanowi ok. 3% nowotworów wykrywanych corocznie na świecie i zajmuje 4. miejsce pod względem śmiertelności wśród nowotworów złośliwych. Agresywny przebieg, późne rozpoznanie oraz oporność na stosowane leczenie powoduje, że 5-letnie przeżycie nie przekracza 5%. Podstawową metodą terapii wczesnych postaci nowotworu jest radykalny zabieg, jednak w chwili rozpoznania u 80-90% chorych proces nowotworowy jest zaawansowany, a guz nieoperacyjny. Jedną z możliwości poprawy wyników leczenia raka trzustki jest stosowanie terapii uzupełniającej. W niniejszym artykule przedstawiono przegląd aktualnych badań z randomizacją dotyczących leczenia adiuwantowego, neoadiuwantowego, monoterapii, terapii skojarzonej oraz leczenia bólu czy roli odżywiania w terapii raka trzustki. AbstractTreatment of pancreatic cancer is a major oncological challenge. Pancreatic cancer remains a highly lethal disease and is the 4 th leading cause of cancer-related deaths in the United States, with a 5-year survival of less than 5%. The poor prognosis of this cancer is due to its propensity for early local invasion and metastasis. Most patients present with advanced disease, precluding curative surgical resection, which remains the only potential curative approach. The adjuvant treatment may improve the prognosis in pancreatic cancer. This article presents a review of randomized clinical trials including adjuvant and neoadjuvant treatment, monotherapy and combination therapy, pain relief and the role of nutrition in pancreatic cancer treatment. WstępLeczenie raka trzustki jest poważnym problemem współczesnej medycyny. Stanowi on ok. 3% nowotworów wykrywanych corocznie na świecie i zajmuje 4. miejsce pod względem śmiertelności wśród nowotworów złośli-wych. Agresywny przebieg, późne rozpoznanie oraz oporność na stosowane leczenie powoduje, że 5-letnie przeżycie nie przekracza 5%, a większość chorych umiera w ciągu 3-6 mies. od rozpoznania. Podstawową metodą terapii wczesnych postaci nowotworu jest radykalny zabieg, jednak w chwili rozpoznania u 80-90% chorych proces nowotworowy jest zaawansowany, a guz nieoperacyjny [1]. Jedną z możliwości poprawy wyników leczenia raka trzustki jest stosowanie terapii uzupełniającej.W niniejszym artykule przedstawiono przegląd aktualnych badań z randomizacją dotyczących leczenia adiuwantowego, neoadiuwantowego, monoterapii, terapii skojarzonej oraz leczenia bólu czy roli odżywiania w terapii raka trzustki.

show abstract

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282

Cited by 131 publications

References 20 publications

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

Randomized trials in exocrine pancreatic cancer

Contact Info

Product

Resources

About